• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    How I treat biliary tract cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Lamarca.pdf
    Size:
    1.170Mb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Lamarca, Angela
    Edeline, J.
    Goyal, L.
    Affiliation
    Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: angela.lamarca@nhs.net. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, USA.
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Management of biliary tract cancers (BTCs) is rapidly evolving. Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Unfortunately relapse rate remains high, and better adjuvant strategies are urgently required. A majority of patients are diagnosed with advanced disease, when chemotherapy with cisplatin and gemcitabine followed by second-line 5-FU and oxaliplatin / irinotecan is the cornerstone of treatment for most patients in the absence of targetable alterations. Targeted therapies, including therapies for tumours with fibroblast growth factor receptor-2 (FGFR-2) fusions, isocitrate dehydrogenase-1 (IDH-1) mutations, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, Human epidermal growth factor-2 (HER-2) amplifications, and/ or microsatellite instability are rapidly changing the treatment paradigm for many patients with advanced BTC, especially for patients with intrahepatic cholangiocarcinoma. Because of this, molecular profiling should be considered early on patients pathway to allow adequate planning of therapy. Ongoing research is likely to clarify the role of immunotherapy, liver-directed therapy, and liver transplant for BTCs in the future.
    Citation
    Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. Vol. 7, ESMO Open. Elsevier BV; 2022. p. 100378.
    Journal
    ESMO Open
    URI
    http://hdl.handle.net/10541/625067
    DOI
    10.1016/j.esmoop.2021.100378
    PubMed ID
    35032765
    Additional Links
    https://dx.doi.org/10.1016/j.esmoop.2021.100378
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.esmoop.2021.100378
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Systemic treatment of advanced or recurrent biliary tract cancer.
    • Authors: Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, Zhang T, Li Q
    • Issue date: 2020 Nov 4
    • Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
    • Authors: Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I
    • Issue date: 2020 Jun
    • The state of therapy modalities in clinic for biliary tract cancer.
    • Authors: Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L
    • Issue date: 2022 Jun 8
    • Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    • Authors: Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN
    • Issue date: 2021 Oct
    • Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    • Authors: Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY
    • Issue date: 2019 Oct
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.